Multiplying the Impact of Opioid Settlement Funds by Investing in Primary Prevention
J Hosp Med
.
2020 Oct;15(10):625-627.
doi: 10.12788/jhm.3455.
Authors
Laura J Faherty
1
2
,
Scott E Hadland
3
4
,
Bradley D Stein
5
6
,
Stephen W Patrick
7
5
8
9
10
Affiliations
1
RAND Corporation, Boston, Massachusetts.
2
School of Medicine, Boston University, Boston, Massachusetts.
3
Department of Pediatrics, Boston Medical Center, Boston, Massachusetts.
4
Division of General Pediatrics, Department of Pediatrics, Boston University, Boston, Massachusetts.
5
RAND Corporation, Pittsburgh, Pennsylvania.
6
School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
7
Department of Health Policy, Vanderbilt University, Nashville, Tennessee.
8
Department of Pediatrics, Vanderbilt University, Nashville, Tennessee.
9
Mildred Stahlman Division of Neonatology, Vanderbilt University, Nashville, Tennessee.
10
Vanderbilt Center for Child Health Policy, Nashville, Tennessee.
PMID:
32853139
PMCID:
PMC7531941
DOI:
10.12788/jhm.3455
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Analgesics, Opioid* / adverse effects
Financial Management*
Humans
Primary Prevention
Substances
Analgesics, Opioid
Grants and funding
L40 DA042434/DA/NIDA NIH HHS/United States
R21 DA045212/DA/NIDA NIH HHS/United States
K23 DA045085/DA/NIDA NIH HHS/United States
R01 DA045729/DA/NIDA NIH HHS/United States
P50 DA046351/DA/NIDA NIH HHS/United States
K23 DA038720/DA/NIDA NIH HHS/United States